154 related articles for article (PubMed ID: 29804387)
1. [Chronic hepatitis C: achievement, challenge and strategy to eliminate as a public health threat].
Wei L
Zhonghua Gan Zang Bing Za Zhi; 2018 Mar; 26(3):161-168. PubMed ID: 29804387
[TBL] [Abstract][Full Text] [Related]
2. [Clinical value of pegylated interferon-α plus ribavirin-based therapy in antiviral treatment of chronic hepatitis C in China].
Zhu F; Zhang QY; Zhang DZ
Zhonghua Gan Zang Bing Za Zhi; 2018 Mar; 26(3):173-174. PubMed ID: 29807402
[TBL] [Abstract][Full Text] [Related]
3. [Selection of direct-acting antiviral agents for chronic hepatitis C infection].
He YJ; Liu ZH; Hou JL
Zhonghua Gan Zang Bing Za Zhi; 2018 Mar; 26(3):169-172. PubMed ID: 29804388
[TBL] [Abstract][Full Text] [Related]
4. [Current status of treatment of chronic hepatitis C and related challenges in the "Pre-DAA Era" in China].
Hu P; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2016 Nov; 24(11):869-873. PubMed ID: 27978936
[TBL] [Abstract][Full Text] [Related]
5. [Guidelines for the prevention and treatment of hepatitis C (2019 version)].
;
Zhonghua Gan Zang Bing Za Zhi; 2019 Dec; 27(12):962-979. PubMed ID: 31941258
[TBL] [Abstract][Full Text] [Related]
6. [A new challenge in clinical practice: resistance to directly acting antivirals in hepatitis C treatment].
Chen ZW; Hu P; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):165-9. PubMed ID: 27095757
[TBL] [Abstract][Full Text] [Related]
7. [Effectiveness and safety of direct-acting antiviral agents for treatment of patients with chronic hepatitis C virus infection].
Yang J; Rao HY
Zhonghua Gan Zang Bing Za Zhi; 2018 Mar; 26(3):175-178. PubMed ID: 29804389
[TBL] [Abstract][Full Text] [Related]
8. [From treatable to curable to eliminated ---- a decade of research progress in the diagnosis and treatment of hepatitis C].
Rao HY; Wei L
Zhonghua Gan Zang Bing Za Zhi; 2021 Feb; 29(2):102-107. PubMed ID: 33685075
[TBL] [Abstract][Full Text] [Related]
9. [In-hospital process for viral hepatitis C screening and management in China (Draft)].
; ; ;
Zhonghua Gan Zang Bing Za Zhi; 2021 Apr; 29(4):319-325. PubMed ID: 33979957
[TBL] [Abstract][Full Text] [Related]
10. A buyers' club to improve access to hepatitis C treatment for vulnerable populations.
Vernaz N; Calmy A; Hurst S; Jackson Y; Negro F; Perrier A; Wolff H
Swiss Med Wkly; 2018 Aug; 148():w14649. PubMed ID: 30141526
[TBL] [Abstract][Full Text] [Related]
11. [Clinical timing and benefit of antiviral treatment for hepatitis C].
Chen LC; Xie Q
Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):164-169. PubMed ID: 28482401
[TBL] [Abstract][Full Text] [Related]
12. [Opportunities and challenges for the treatment of chronic hepatitis C].
Luo BF; Wei L
Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):161-163. PubMed ID: 28482400
[TBL] [Abstract][Full Text] [Related]
13. Addressing the Challenges of Hepatitis C Virus Resistance and Treatment Failure.
Colpitts CC; Baumert TF
Viruses; 2016 Aug; 8(8):. PubMed ID: 27537906
[TBL] [Abstract][Full Text] [Related]
14. Review of direct-acting antiviral agents for the treatment of chronic hepatitis C.
Shah N; Pierce T; Kowdley KV
Expert Opin Investig Drugs; 2013 Sep; 22(9):1107-21. PubMed ID: 23735127
[TBL] [Abstract][Full Text] [Related]
15. Does antiviral therapy reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis C?
Michielsen P; Ho E; Francque S
Minerva Gastroenterol Dietol; 2012 Mar; 58(1):65-79. PubMed ID: 22419005
[TBL] [Abstract][Full Text] [Related]
16. [Price analyses on direct-acting antiviral drugs of hepatitis C].
Duan CAX; Sui BY; Chen ZD; Zhao K
Zhonghua Yu Fang Yi Xue Za Zhi; 2020 Oct; 54(10):1161-1164. PubMed ID: 33115205
[TBL] [Abstract][Full Text] [Related]
17. [Direct-acting antiviral treatment of chronic hepatitis C infection].
Grüner N; Gerbes A
MMW Fortschr Med; 2015 Apr; 157(8):57-60. PubMed ID: 26012687
[No Abstract] [Full Text] [Related]
18. [Hepatitis C-related hepatocellular carcinoma and the treatment with direct-acting antiviral agents].
Liu X; Gao YH; Niu JQ
Zhonghua Gan Zang Bing Za Zhi; 2017 Dec; 25(12):944-947. PubMed ID: 29325299
[TBL] [Abstract][Full Text] [Related]
19. [Potential application of sofosbuvir-based treatment for chronic hepatitis C in China].
Zhang QF; Zhang DZ
Zhonghua Gan Zang Bing Za Zhi; 2018 Mar; 26(3):233-237. PubMed ID: 29804397
[TBL] [Abstract][Full Text] [Related]
20. Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials.
Arias A; Aguilera A; Soriano V; Benítez-Gutiérrez L; Lledó G; Navarro D; Treviño A; Otero E; Peña JM; Cuervas-Mons V; de Mendoza C
Antivir Ther; 2017; 22(4):307-312. PubMed ID: 27341294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
